People · Operator
Named in public records as an officer, director or promoter · active 2016–2018 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Receptor Holdings, Inc. | — | Pharmaceuticals | Series B | $36.2M | $140.9M | 2018 |
| Receptor Life Sciences, Inc. | — | Other | Series A | $7.6M | $114.6M | 2016 |
Gregory Wesner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gregory Wesner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Arthur Rubinfeld | 2 | 4 |
| Traci Carman | 2 | 2 |
| Gregory Mayes | 1 | 5 |
| Warren Lammert | 1 | 3 |
| Mark Theeuwes | 1 | 3 |
| David Thomson | 1 | 2 |
| Jim Weissman | 1 | 1 |
| Greg Wesner | 1 | 1 |
| Orrin Devinsky, MD, PhD | 1 | 1 |
| Andrea Leone-Bay | 1 | 1 |
| Stephen Hoffman, MD, PhD | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.